Eli Lilly said it is positioned to file a Biologics License Application for retatrutide after additional Phase 3 obesity results cleared two more late-stage studies. The program, often described as a “triple-G” incretin agonist, continued to show substantial weight-loss effects across tested doses. In Triumph-2 (obesity/overweight with type 2 diabetes) and Triumph-3 (severe obesity with cardiovascular disease), the highest 12 mg doses produced peak weight loss of 20.8% and 22.6% at 80 weeks, respectively. Lower-dose outcomes included 19.1% weight loss for the 9 mg arm in Triumph-2 and 21.6% in the 12 mg arm versus placebo declines of 4% and 3.2% across the studies. Lilly’s disclosures also noted that questions remain about whether retatrutide’s benefits translate into cardiovascular risk reduction at a level that would meet expectations for a label expansion. Separately, one report emphasized that reductions in cardiovascular risk were not clearly proven in the new readouts. Lilly said the regulatory filing pathway is enabled by the accumulated Phase 3 data package, with an anticipated application timing early next year as it seeks to broaden retatrutide’s clinical footprint.